Table 3.
Topical delivery of certain drugs using PFOB NPs as potential carriers for cancer and atherosclerosis therapies
| Therapy | Shell material/loaded drug | Target epitope | Drug localization | Drug transport mechanism | References |
|---|---|---|---|---|---|
| Loading of antitumor drugs for cancer therapy | Lipid/melittin | – | Lipid monolayer | Lipid exchange | 96 |
| Lipid/PTX | TN-C | Lipid monolayer | Not determined | 33 | |
| Lipid/c-Myc inhibitor prodrug | αvβ3 integrin | Lipid monolayer | Lipid exchange | 104, 105 | |
| Bi2Se3/– | – | – | – | 106 | |
| PLGA/doxorubicin | FR | Polymer shell | No exposure | 17 | |
| PLGA-PEG/PTX | – | Polymer shell | No exposure | 107 | |
| PLGA/doxorubicin | LRP-1 | Center of the NPs | No exposure | 112 | |
| Antiangiogenesis drugs for cancer therapy | Lipid/fumagillin | α5β1 integrin | Lipid monolayer | Lipid exchange | 119 |
| Lipid/fumagillin | αvβ3 integrin | Lipid monolayer | Lipid exchange | 120, 121 | |
| Lipid/taxane prodrug | αvβ3 integrin | Lipid monolayer | Lipid exchange | 122 | |
| Antiangiogenesis drugs for atherosclerosis therapy | Lipid/fumagillin | αvβ3 integrin | Lipid monolayer | Lipid exchange | 128, 129 |
Abbreviations: FR, folate receptor; LRP-1, low-density lipoprotein receptor-related protein-1; NPs, nanoparticles; PFOB NPs, perfluorooctylbromide nanoparticles; PLGA, poly(lactide-co-glycolide) acid; PLGA-PEG, poly(lactide-co-glycolide) acid-polyethylene glycol; PTX, paclitaxel; TN-C, tenascin-C.